Chemerin is dysregulation in numerous solid cancers. However, only little is known about the role of chemerin in acute myeloid leukemia (AML). In this study, we aimed to investigate the expression and clinical significance of recently described chemerin in acute myeloid leukemia (AML). The expression of chemerin in 149 patients with de novo AML and 35 normal controls was quantified by Real-time quantitative PCR (RQ-PCR). Chemerin was down-expressed in AML compared with controls (P=0.042). A receiver operating characteristic (ROC) curve revealed that chemerin expression could differentiate patients with AML from control subjects (AUC=0.611, 95% CI: 0.490-0.732; P=0.042) respectively. The cohort of AML patients was divided into two groups according to the cut-off value of 0.0826 (79% sensitivity and 54% specificity, respectively). In addition, the AML patients with low chemerin expression had significantly shorter overall survival (OS) than those with high chemerin expression (P=0.049). Moreover, multivariate survival analysis confirmed that chemerin was an independent prognostic factor for AML patients. In conclusion, downregulation of chemerin might be a useful diagnostic and prognostic factor for AML patients.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5696201PMC
http://dx.doi.org/10.18632/oncotarget.21440DOI Listing

Publication Analysis

Top Keywords

aml patients
16
acute myeloid
12
myeloid leukemia
12
chemerin expression
12
chemerin
11
aml
9
expression chemerin
8
chemerin acute
8
leukemia aml
8
prognostic factor
8

Similar Publications

Background: Acute myeloid leukemia (AML) is an aggressive hematological neoplasm. Little improvement in survival rates has been achieved over the past few decades. Necroptosis has relationship with certain types of malignancies outcomes.

View Article and Find Full Text PDF

The FLT3 gene frequently undergoes mutations in acute myeloid leukemia (AML), with internal tandem duplications (ITD) and tyrosine kinase domain (TKD) point mutations (PMs) being most common. Recently, PMs and deletions in the FLT3 juxtamembrane domain (JMD) have been identified, but their biological and clinical significance remains poorly understood. We analyzed 1660 patients with de novo AML and found FLT3-JMD mutations, mostly PMs, in 2% of the patients.

View Article and Find Full Text PDF

Background: Prior research indicates that engaging in physical activity during chemotherapy can positively influence both physical and psychological parameters in individuals with hematological neoplasms. However, the most effective type, level, intensity, and frequency of exercise remains unclear.

Patients And Methods: We enrolled 53 patients to a clinical trial assessing a partly supervised hybrid training program including both strength and endurance components, commencing at onset of induction therapy (T0) for hematological malignancies, including AML (n = 29), ALL (n = 5), and NHL (n = 19).

View Article and Find Full Text PDF

AI generated synthetic STIR of the lumbar spine from T1 and T2 MRI sequences trained with open-source algorithms.

AJNR Am J Neuroradiol

January 2025

From the Orthopedic Data Innovation Lab (ODIL), Hospital for Special Surgery (A.M.L.S., M.A.F.), Department of Radiology and Imaging, Hospital for Special Surgery Centre (E.E.X, Z.I, E.T.T, D.B.S, J.L.C)and Department of Population Health Sciences, Weill Cornell Medicine (M.A.F), New York, New York, USA.

Background And Purpose: To train and evaluate an open-source generative adversarial networks (GANs) to create synthetic lumbar spine MRI STIR volumes from T1 and T2 sequences, providing a proof-of-concept that could allow for faster MRI examinations.

Materials And Methods: 1817 MRI examinations with sagittal T1, T2, and STIR sequences were accumulated and randomly divided into training, validation, and test sets. GANs were trained to create synthetic STIR volumes using the T1 and T2 volumes as inputs, optimized using the validation set, then applied to the test set.

View Article and Find Full Text PDF

Therapy-related acute myeloid leukemia (t-AML), which develops after cytotoxic therapy, has a poorer prognosis. Although allogeneic hematopoietic stem cell transplantation (allo-HSCT) is a potential cure, its efficacy varies among patients. In this retrospective study, we analyzed 154 patients with t-AML who underwent hematopoietic stem cell transplantation (HSCT) at our institution to determine their clinical characteristics and develop a prognostic nomogram.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!